Context Therapeutics Inc
NASDAQ:CNTX
Income Statement
Earnings Waterfall
Context Therapeutics Inc
Income Statement
Context Therapeutics Inc
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Interest Expense |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(3)
|
(3)
|
(7)
|
(8)
|
(11)
|
(13)
|
(12)
|
(15)
|
(15)
|
(19)
|
(20)
|
(22)
|
(25)
|
(22)
|
(20)
|
(33)
|
(30)
|
(32)
|
(39)
|
(30)
|
|
| Selling, General & Administrative |
(1)
|
(1)
|
(1)
|
(2)
|
(4)
|
(5)
|
(7)
|
(8)
|
(8)
|
(8)
|
(8)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(8)
|
(8)
|
|
| Research & Development |
(2)
|
(2)
|
(6)
|
(6)
|
(7)
|
(8)
|
(5)
|
(7)
|
(8)
|
(11)
|
(12)
|
(15)
|
(18)
|
(15)
|
(13)
|
(25)
|
(23)
|
(24)
|
(31)
|
(23)
|
|
| Operating Income |
(3)
N/A
|
(3)
-13%
|
(7)
-151%
|
(8)
-13%
|
(11)
-28%
|
(13)
-24%
|
(12)
+8%
|
(15)
-21%
|
(15)
-5%
|
(19)
-21%
|
(20)
-7%
|
(22)
-11%
|
(25)
-14%
|
(22)
+11%
|
(20)
+10%
|
(33)
-64%
|
(30)
+9%
|
(32)
-7%
|
(39)
-21%
|
(30)
+22%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
9
|
8
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
3
|
4
|
4
|
4
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
|
| Pre-Tax Income |
7
N/A
|
5
-26%
|
(8)
N/A
|
(8)
-7%
|
(10)
-29%
|
(13)
-24%
|
(12)
+8%
|
(14)
-20%
|
(15)
-3%
|
(18)
-19%
|
(19)
-6%
|
(21)
-11%
|
(24)
-15%
|
(21)
+11%
|
(19)
+13%
|
(30)
-60%
|
(27)
+10%
|
(27)
-2%
|
(34)
-24%
|
(26)
+22%
|
|
| Net Income | |||||||||||||||||||||
| Income from Continuing Operations |
7
|
5
|
(8)
|
(8)
|
(10)
|
(13)
|
(12)
|
(14)
|
(15)
|
(18)
|
(19)
|
(21)
|
(24)
|
(21)
|
(19)
|
(30)
|
(27)
|
(27)
|
(34)
|
(26)
|
|
| Net Income (Common) |
7
N/A
|
5
-26%
|
(8)
N/A
|
(8)
-7%
|
(10)
-29%
|
(13)
-24%
|
(12)
+8%
|
(14)
-20%
|
(15)
-3%
|
(18)
-19%
|
(19)
-6%
|
(21)
-11%
|
(24)
-15%
|
(21)
+11%
|
(19)
+13%
|
(30)
-60%
|
(27)
+10%
|
(27)
-2%
|
(34)
-24%
|
(26)
+22%
|
|
| EPS (Diluted) |
0.61
N/A
|
0.45
-26%
|
-0.69
N/A
|
-0.74
-7%
|
-0.65
+12%
|
-0.81
-25%
|
-0.74
+9%
|
-0.9
-22%
|
-0.93
-3%
|
-1.11
-19%
|
-1.17
-5%
|
-1.3
-11%
|
-1.5
-15%
|
-1.33
+11%
|
-0.33
+75%
|
-0.37
-12%
|
-0.46
-24%
|
-0.28
+39%
|
-0.35
-25%
|
-0.28
+20%
|
|